Dewpoint Therapeutics
Ann Boija is Head of Cancer Biology at Dewpoint. She has longstanding expertise in gene control, cancer biology, and condensate biology. Ann is passionate about advancing basic biomedical science into medicine to alter the course of cancer and to improve human health. Ann has a Master’s degree in Biomedical Sciences from Umeå University and a PhD in Biology from Stockholm University, Sweden. She did her postdoctoral training—and later served as a Senior Researcher—in the laboratory of Richard A. Young at the Whitehead Institute of the Massachusetts Institute of Technology (MIT). During her time at MIT, she led pioneering research focused on the role of condensates in gene control and cancer therapeutic drug activity.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.